Pfizer, Moderna, J&J to make 240 mln COVID-19 vaccine doses by March end

Pfizer, Moderna, and Johnson & Johnson firms are set to produce more than 240 million COVID-19 vaccine doses to the US, the three firms expressed on Tuesday.

Both Pfizer and Moderna undertook to produce a total of 220 million doses by the end of March.

On the other hand, Johnson & Johnson showed a commitment to producing 20 million doses at the end of the same month too.

However, Johnson & Johnson COVID-19 vaccine is still waiting for FDA approval for emergency use.

The firm's vice president of medical affairs Dr. Richard Nettles explained: "If the emergency use authorization is received this week, we hope to contribute to ending this pandemic as soon as possible."

Alongside the three mentioned vaccines, a fourth one could be available in the US in April which is AstraZeneca.

AstraZeneca company is seeking to be authorized in the US by the FDA.

The executive vice president and president of AstraZeneca's business unit Dr. Ruud Dobber revealed that AstraZeneca is ready for producing at least 30 million doses after the authorization by the end of April.